Liu Bing-qian, Wang Yi-kun, Wu Yu-dong, Wei Jin-xing, Li Xin
Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Email:
Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Zhonghua Zhong Liu Za Zhi. 2013 Nov;35(11):828-32.
To detect the expression of prostate cancer antigen-1 (PCA-1) in prostate cancer, and to analyze the effects of downregulation of PCA-1 expression on malignant biological behavior of prostate cancer LNCaP cells, and to explore their possible molecular mechanisms.
PCA-1-siRNA and control siRNA were transfected into LNCaP cells with lipofectamine 2000. The cell cycle, proliferation and migration were determined by methyl thiazolyl tetrazolium (MTT) assay, flow cytometry and Transwell chambers, respectively. Western blotting was used to detect the expression of cyclin E, matrix metallopeptidase 9 (MMP-9) and p21. Immunohistochemistry was used to detect the expression of PCA-1 protein in 126 cases of prostate cancer and 88 cases of benign prostatic hyperplasia (BPH).
The positive rate of PCA-1 expression was 77.8% (98/126) in prostate cancer, and 10.2% (9/88) in BPH, and its expression was not significantly related to age, prostate specific antigen (PSA), Eastern Cooperative Oncology Group (ECOG) score (P > 0.05), and was associated with Gleason score, TNM staging and bone metastasis (P < 0.05). Downregulation of PCA-1 expression inhibited cell proliferation, arrested cell cycle at S phase and decreased cell migration of LNCaP cells. The downregulation of PCA-1 expression decreased the expression of Bcl-xl, cyclin E and MMP-9 proteins, but increased the expression of p21 proteins.
PCA-1 may play an important role in the development of prostate cancer. The downregulation of PCA-1 expression can lead to changes in the proliferation, cell cycle and migration of prostate cancer LNCaP cells, and these effects may be associated with the decrease of Bcl-xl, cyclin E and MMP-9 proteins and increase of p21 protein.
检测前列腺癌抗原-1（PCA-1）在前列腺癌中的表达，分析PCA-1表达下调对前列腺癌LNCaP细胞恶性生物学行为的影响，并探讨其可能的分子机制。
用脂质体2000将PCA-1-siRNA和对照siRNA转染至LNCaP细胞。分别采用甲基噻唑基四氮唑蓝（MTT）法、流式细胞术和Transwell小室检测细胞周期、增殖和迁移情况。采用蛋白质免疫印迹法检测细胞周期蛋白E、基质金属蛋白酶9（MMP-9）和p21的表达。采用免疫组织化学法检测126例前列腺癌和88例良性前列腺增生（BPH）组织中PCA-1蛋白的表达。
PCA-1在前列腺癌中的阳性表达率为77.8%（98/126），在BPH中为10.2%（9/88），其表达与年龄、前列腺特异性抗原（PSA）、东部肿瘤协作组（ECOG）评分无显著相关性（P>0.05），与Gleason评分、TNM分期和骨转移相关（P<0.05）。PCA-1表达下调抑制LNCaP细胞增殖，使细胞周期停滞于S期并降低细胞迁移能力。PCA-1表达下调使Bcl-xl蛋白、细胞周期蛋白E和MMP-9蛋白表达降低，但使p21蛋白表达增加。
PCA-1可能在前列腺癌发生发展中起重要作用。PCA-1表达下调可导致前列腺癌LNCaP细胞增殖、细胞周期和迁移发生改变，这些作用可能与Bcl-xl蛋白、细胞周期蛋白E和MMP-9蛋白表达降低及p21蛋白表达增加有关。
